SOURCE: GlobeImmune, Inc.

June 24, 2008 13:00 ET

FierceBiotech Names GlobeImmune as One of the "Fierce 15" Biotech Companies of 2008

GlobeImmune Is "Fierce," on Leading Edge of Biotech

LOUISVILLE, CO--(Marketwire - June 24, 2008) - FierceBiotech and GlobeImmune, Inc. announced today that GlobeImmune has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech evaluated hundreds of privately held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. GlobeImmune was determined to be one of the "fiercest," proven by their creativity and innovations in the industry.

An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.

"This year will put everyone at GlobeImmune to a crucial test," said John Carroll, Editor of FierceBiotech. "It has two therapies in the clinic, unusual for any small biotech. But a major venture round last fall -- its third -- has provided the biotech enough money to see if its drug platform -- engineering a T-cell attack on diseased cells -- can produce the kind of definitive data that will validate the approach."

GlobeImmune is a private Colorado-based company developing active immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. The Company's lead infectious disease product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection. The Company has completed enrollment of a randomized phase 2 trial of GI-5005 in combination with the current standard of care. GI-5005 is designed to complement both the current and emerging standard of care for hepatitis C infection through the elimination of chronically infected cells. The Company's lead oncology product, GI-4000, is designed to be a treatment for cancers of the lung and gastrointestinal tract that are driven by mutations in the Ras oncogene. A randomized, placebo-controlled phase 2 trial in patients with resectable pancreatic cancer in combination with adjuvant gemcitabine is ongoing. Additionally, a phase 2 trial in non-small cell lung cancer is ongoing at Memorial Sloan Kettering Cancer Center.

"Being selected as a member of the 'Fierce 15' is an honor that highlights GlobeImmune's potential to make a significant impact in the biotech market," said Jeff Rona, GlobeImmune's Chief Business Officer

The "Fierce 15" celebrates the spirit of being "fierce" -- championing innovation and creativity, even in the face of intense competition. The complete list of "Fierce 15" companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at

About FierceMarkets

FierceMarkets is a digital business media company serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets' publications reach more than 450,000 executives in over 100 countries every business day. Current publications include The Business VoIP Report (, FierceBioResearcher (, FierceBiotech (, FierceBroadbandWireless (, FierceCIO (, Fierce CIO: Tech Watch (, FierceDeveloper (, FierceFinance (, FierceFinanceIT (, FierceHealthCare (, FierceHealthFinance (, FierceHealthIT (, FierceIPTV (, FierceMobileContent (, FierceMobileIT (, FierceOnlineVideo (, FiercePharma (, FierceSarbox (, FierceTelecom (, FierceVaccines (, FierceVoIP (, FierceWireless (, and FierceWireless: Europe (